DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01235819

CompletedPhase 4

Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus

Asset

Exenatide

GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

20

actual

Study population

Type 1 diabetes

Key I/E criterion

—

Primary endpoint

•Insulin requirement

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01235819
Org study IDDM/CHCC/03/2010

Timeline

Milestones

Study first posted2010-11-08estimated
Last update posted2016-07-27estimated
Study start2010-11 (month precision)
Primary completion2011-09actual (month precision)
Study completion2011-09actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Type 1 diabetes

Eligibility

Who can enroll

Minimum age12 Years
Maximum age30 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•T1DM <3 months
•GAD Antibody+ or Stimulated C peptide<0.5 ng/ml
•Ketosis at onset
•Age < 30 yr

Exclusion criteria

•Age > 30 yr
•Pancreas disease
•Significant systemic disease

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

2 endpoints
Primary/protocol endpoint

change in insulin requirement

Time frame:one year

change from baseline, improvement

Secondary/protocol endpoint

C peptide response

Time frame:at the end of one year

C-peptide AUC

change from baseline, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.